Found 284 Results
Page 1 of 29
Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]
07/29/2021
Danièle Guyot-Caparros, outgoing Chairwoman, remains an independent member of the Board of Directors and Chair of the Audit Committee […]
Tags: Financials & Corporate
All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]
06/10/2021
This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]
06/09/2021
This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]
05/31/2021
Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
05/21/2021
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Tags: Financials & Corporate
04/23/2021
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
04/21/2021
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
04/12/2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
Tags: AsiDNA™, OX401
04/08/2021
Page 1 of 29
